Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Pulse Biosciences, Inc.

NASDAQ: PLSE · Industrial Applications and Services · 7 alerts · CIK 1625101

Pulse Biosciences, Inc. stories on ALFA USA NewsRead the news →
Share price
$46.36Close, Nov 16
Market cap
$3.41B
Shares outstanding
73.55MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Pulse Biosciences, Inc. filings on SEC EDGAR ↗

4:11 PM ET 10-Q
Financial Results

Pulse Biosciences Q3 2026 Results: Net Loss of $23.1M, Loss Widens

Pulse Biosciences reported a net loss of $66.3 million for the nine months ended September 30, 2026, compared to $55.3 million in the prior year period, driven by increased research and development expenses. The company significantly strengthened its balance sheet through an at-the-market offering program, raising $142.7 million and ending the period with $189.2 million in cash, cash equivalents, and marketable securities.

Key figure
Net loss $23.1M
4:11 PM ET 8-K
Financial Results

Pulse Biosciences Financial Results

Pulse Biosciences reported third quarter 2026 financial results, highlighted by the completion of enrollment in its NANOPULSE-AF U.S. pivotal IDE study three months ahead of schedule. The company ended the quarter with $189.2 million in cash and equivalents, bolstered by $95.8 million in net proceeds raised through its ATM programs during the period.

“Pulse Biosciences delivered several major milestones since the second quarter, led by completing enrollment in our U.S. pivotal IDE study in just six months, three months ahead of plan. That speed reflects the growing enthusiasm physicians have shown for the nPulse catheter since their very first cases.”

Paul LaViolette, CEO and Co Chairman of Pulse Biosciences

“With NANOPULSE-AF fully enrolled, and the capital to execute, we are now focused on preparations for launch readiness, additional data readouts, and regulatory submissions.”

Paul LaViolette, CEO and Co Chairman of Pulse Biosciences

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.